#47 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians should understand that cannabis concentrates like dabs contain significantly higher THC potency than traditional flower, which has direct implications for dosing counseling and managing patients at risk for cannabis use disorder or adverse effects like psychosis. The emerging research on terpene-cannabinoid interactions suggests that product composition varies substantially, making standardized patient education and risk stratification more complex when patients self-select cannabis products. As dab consumption grows in popularity, clinicians need updated knowledge about concentrated product pharmacology to accurately assess intake levels, predict symptom severity, and provide evidence-based guidance on safer consumption methods.
This article discusses cannabis concentrate products in the context of “National Dab Day” and references emerging pharmacological evidence that cannabis terpenes enhance THC’s activation of cannabinoid receptors. The finding that terpenes modulate cannabinoid receptor activity has direct clinical relevance, as it suggests that the therapeutic and psychoactive effects of cannabis products depend not solely on THC content but on the full chemical profile of the plant material. Clinicians prescribing or recommending cannabis should be aware that concentrated products like dabs may deliver substantially different pharmacological effects than whole-plant cannabis due to variations in terpene composition and concentration ratios. This knowledge is particularly important for patients seeking consistent dosing or specific therapeutic outcomes, as currently available products lack standardized labeling of terpene profiles. Understanding the entourage effect between cannabinoids and terpenes helps clinicians counsel patients more accurately about product selection and potential variability in clinical effects.
“Concentrated cannabis products like dabs deliver significantly higher THC levels than flower, which can be particularly risky for patients with cannabinoid hyperemesis syndrome, psychosis risk, or those new to cannabis, so I counsel caution regardless of the occasion or marketing around it. The preliminary work on terpene-cannabinoid interactions is interesting from a pharmacology standpoint, but we need rigorous human trials before making clinical claims about enhanced effects or therapeutic benefits.”
💨 As cannabis concentrates gain popularity and marketing events like “Dab Day” normalize consumption of high-potency products, clinicians should recognize that concentrated forms deliver substantially higher THC doses per use compared to traditional flower, potentially increasing risks of acute cannabis hyperemesis syndrome, psychosis, or cannabinoid hyperemesis in susceptible patients. The emerging research on terpene-cannabinoid interactions adds another layer of complexity, suggesting that product composition beyond simple THC percentage may influence individual responses, though clinical translation of this pharmacology remains incomplete. When taking substance use histories, providers should specifically inquire about concentrate use and frequency, as patients may underestimate the potency and dependence potential of these products relative to their perceived casual use. Given the accelerating normalization of high-potency cannabis through social media and branded consumption events, clinicians need updated knowledge about concentrate-specific harms to counsel patients effectively and recognize related presentations in their practice.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
